"Platelet Factor 4" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A CXC chemokine that is found in the alpha granules of PLATELETS. The protein has a molecular size of 7800 kDa and can occur as a monomer, a dimer or a tetramer depending upon its concentration in solution. Platelet factor 4 has a high affinity for HEPARIN and is often found complexed with GLYCOPROTEINS such as PROTEIN C.
| Descriptor ID |
D010978
|
| MeSH Number(s) |
D12.644.276.374.200.120.900 D12.776.124.125.720 D12.776.467.374.200.120.900 D23.119.940 D23.125.300.120.900 D23.469.200.120.900 D23.529.374.200.120.900
|
| Concept/Terms |
Platelet Factor 4- Platelet Factor 4
- Chemokine CXCL4
- CXCL4, Chemokine
- PF4 (Platelet Factor 4)
- gamma-Thromboglobulin
- gamma Thromboglobulin
- Heparin Neutralizing Protein
- Antiheparin Factor
- CXCL4 Chemokine
- Chemokine, CXCL4
|
Below are MeSH descriptors whose meaning is more general than "Platelet Factor 4".
Below are MeSH descriptors whose meaning is more specific than "Platelet Factor 4".
This graph shows the total number of publications written about "Platelet Factor 4" by people in this website by year, and whether "Platelet Factor 4" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2010 | 1 | 0 | 1 |
| 2011 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2016 | 1 | 1 | 2 |
| 2017 | 7 | 2 | 9 |
| 2018 | 7 | 3 | 10 |
| 2019 | 1 | 1 | 2 |
| 2020 | 0 | 1 | 1 |
| 2021 | 13 | 16 | 29 |
To return to the timeline, click here.
Below are the most recent publications written about "Platelet Factor 4" by people in Profiles.
-
Clinical Characteristics and Pharmacological Management of COVID-19 Vaccine-Induced Immune Thrombotic Thrombocytopenia With Cerebral Venous Sinus Thrombosis: A Review. JAMA Cardiol. 2021 12 01; 6(12):1451-1460.
-
Anti-platelet factor 4 antibodies causing VITT do not cross-react with SARS-CoV-2 spike protein. Blood. 2021 10 07; 138(14):1269-1277.
-
No Correlation between Anti-PF4 and Anti-SARS-CoV-2 Antibodies after ChAdOx1 nCoV-19 Vaccination. N Engl J Med. 2021 09 30; 385(14):1334-1336.
-
An Update on COVID-19 Vaccine Induced Thrombotic Thrombocytopenia Syndrome and Some Management Recommendations. Molecules. 2021 Aug 18; 26(16).
-
Venous Thromboembolism and Mild Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. Thromb Haemost. 2021 12; 121(12):1677-1680.
-
Intracerebral Hemorrhage due to Thrombosis with Thrombocytopenia Syndrome after Vaccination against COVID-19: the First Fatal Case in Korea. J Korean Med Sci. 2021 Aug 09; 36(31):e223.
-
Interactions of Spike-RBD of SARS-CoV-2 and Platelet Factor 4: New Insights in the Etiopathogenesis of Thrombosis. Int J Mol Sci. 2021 Aug 09; 22(16).
-
Malignant cerebral infarction after ChAdOx1 nCov-19 vaccination: a catastrophic variant of vaccine-induced immune thrombotic thrombocytopenia. Nat Commun. 2021 08 02; 12(1):4663.
-
Prothrombotic immune thrombocytopenia after COVID-19 vaccination. Blood. 2021 07 29; 138(4):350-353.
-
Frequency of positive anti-PF4/polyanion antibody tests after COVID-19 vaccination with ChAdOx1 nCoV-19 and BNT162b2. Blood. 2021 07 29; 138(4):299-303.